Cargando…
Allosteric Inhibition of the SARS‐CoV‐2 Main Protease: Insights from Mass Spectrometry Based Assays
The SARS‐CoV‐2 main protease (M(pro)) cleaves along the two viral polypeptides to release non‐structural proteins required for viral replication. M(Pro) is an attractive target for antiviral therapies to combat the coronavirus‐2019 disease. Here, we used native mass spectrometry to characterize the...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461284/ https://www.ncbi.nlm.nih.gov/pubmed/32841477 http://dx.doi.org/10.1002/anie.202010316 |
_version_ | 1783576736318881792 |
---|---|
author | El‐Baba, Tarick J. Lutomski, Corinne A. Kantsadi, Anastassia L. Malla, Tika R. John, Tobias Mikhailov, Victor Bolla, Jani R. Schofield, Christopher J. Zitzmann, Nicole Vakonakis, Ioannis Robinson, Carol V. |
author_facet | El‐Baba, Tarick J. Lutomski, Corinne A. Kantsadi, Anastassia L. Malla, Tika R. John, Tobias Mikhailov, Victor Bolla, Jani R. Schofield, Christopher J. Zitzmann, Nicole Vakonakis, Ioannis Robinson, Carol V. |
author_sort | El‐Baba, Tarick J. |
collection | PubMed |
description | The SARS‐CoV‐2 main protease (M(pro)) cleaves along the two viral polypeptides to release non‐structural proteins required for viral replication. M(Pro) is an attractive target for antiviral therapies to combat the coronavirus‐2019 disease. Here, we used native mass spectrometry to characterize the functional unit of M(pro). Analysis of the monomer/dimer equilibria reveals a dissociation constant of K (d)=0.14±0.03 μM, indicating M(Pro) has a strong preference to dimerize in solution. We characterized substrate turnover rates by following temporal changes in the enzyme‐substrate complexes, and screened small molecules, that bind distant from the active site, for their ability to modulate activity. These compounds, including one proposed to disrupt the dimer, slow the rate of substrate processing by ≈35 %. This information, together with analysis of the x‐ray crystal structures, provides a starting point for the development of more potent molecules that allosterically regulate M(Pro) activity. |
format | Online Article Text |
id | pubmed-7461284 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-74612842020-09-02 Allosteric Inhibition of the SARS‐CoV‐2 Main Protease: Insights from Mass Spectrometry Based Assays El‐Baba, Tarick J. Lutomski, Corinne A. Kantsadi, Anastassia L. Malla, Tika R. John, Tobias Mikhailov, Victor Bolla, Jani R. Schofield, Christopher J. Zitzmann, Nicole Vakonakis, Ioannis Robinson, Carol V. Angew Chem Int Ed Engl Communications The SARS‐CoV‐2 main protease (M(pro)) cleaves along the two viral polypeptides to release non‐structural proteins required for viral replication. M(Pro) is an attractive target for antiviral therapies to combat the coronavirus‐2019 disease. Here, we used native mass spectrometry to characterize the functional unit of M(pro). Analysis of the monomer/dimer equilibria reveals a dissociation constant of K (d)=0.14±0.03 μM, indicating M(Pro) has a strong preference to dimerize in solution. We characterized substrate turnover rates by following temporal changes in the enzyme‐substrate complexes, and screened small molecules, that bind distant from the active site, for their ability to modulate activity. These compounds, including one proposed to disrupt the dimer, slow the rate of substrate processing by ≈35 %. This information, together with analysis of the x‐ray crystal structures, provides a starting point for the development of more potent molecules that allosterically regulate M(Pro) activity. John Wiley and Sons Inc. 2020-10-15 2020-12-21 /pmc/articles/PMC7461284/ /pubmed/32841477 http://dx.doi.org/10.1002/anie.202010316 Text en © 2020 The Authors. Published by Wiley-VCH GmbH https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Communications El‐Baba, Tarick J. Lutomski, Corinne A. Kantsadi, Anastassia L. Malla, Tika R. John, Tobias Mikhailov, Victor Bolla, Jani R. Schofield, Christopher J. Zitzmann, Nicole Vakonakis, Ioannis Robinson, Carol V. Allosteric Inhibition of the SARS‐CoV‐2 Main Protease: Insights from Mass Spectrometry Based Assays |
title | Allosteric Inhibition of the SARS‐CoV‐2 Main Protease: Insights from Mass Spectrometry Based Assays
|
title_full | Allosteric Inhibition of the SARS‐CoV‐2 Main Protease: Insights from Mass Spectrometry Based Assays
|
title_fullStr | Allosteric Inhibition of the SARS‐CoV‐2 Main Protease: Insights from Mass Spectrometry Based Assays
|
title_full_unstemmed | Allosteric Inhibition of the SARS‐CoV‐2 Main Protease: Insights from Mass Spectrometry Based Assays
|
title_short | Allosteric Inhibition of the SARS‐CoV‐2 Main Protease: Insights from Mass Spectrometry Based Assays
|
title_sort | allosteric inhibition of the sars‐cov‐2 main protease: insights from mass spectrometry based assays |
topic | Communications |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461284/ https://www.ncbi.nlm.nih.gov/pubmed/32841477 http://dx.doi.org/10.1002/anie.202010316 |
work_keys_str_mv | AT elbabatarickj allostericinhibitionofthesarscov2mainproteaseinsightsfrommassspectrometrybasedassays AT lutomskicorinnea allostericinhibitionofthesarscov2mainproteaseinsightsfrommassspectrometrybasedassays AT kantsadianastassial allostericinhibitionofthesarscov2mainproteaseinsightsfrommassspectrometrybasedassays AT mallatikar allostericinhibitionofthesarscov2mainproteaseinsightsfrommassspectrometrybasedassays AT johntobias allostericinhibitionofthesarscov2mainproteaseinsightsfrommassspectrometrybasedassays AT mikhailovvictor allostericinhibitionofthesarscov2mainproteaseinsightsfrommassspectrometrybasedassays AT bollajanir allostericinhibitionofthesarscov2mainproteaseinsightsfrommassspectrometrybasedassays AT schofieldchristopherj allostericinhibitionofthesarscov2mainproteaseinsightsfrommassspectrometrybasedassays AT zitzmannnicole allostericinhibitionofthesarscov2mainproteaseinsightsfrommassspectrometrybasedassays AT vakonakisioannis allostericinhibitionofthesarscov2mainproteaseinsightsfrommassspectrometrybasedassays AT robinsoncarolv allostericinhibitionofthesarscov2mainproteaseinsightsfrommassspectrometrybasedassays |